Two monoclonal antibodies for Αβ, lecanemab and donanemab, have been approved by US Food and Drug Administration for clearing Αβ plaques and decelerating cognitive decline of AD patients in the early stages [4]. The gene discussed is PPIB; the disease is Alzheimer disease.